Genmab — Marts 2020
-
Der er ikke ord for, hvor uforstående jeg er overfor at der på Syddansk Universitet (hvor jeg studerer), er blevet lukket alle kantiner, større forsamlings lokaler osv. Men forelæsninger for +200 elever stadig ikke er aflyst og folk sidder som sild i en tønde. Det er 2020, luk hele lortet når de allerede er i gang, og kør virtuel undervisning. Altså hvor svært kan det være
-
De vil have at du bliver smittet Rune eller et vist antal, så virusset spredes ud over flere mdr. Den kan ikke inddæmmes så samfundsøkonomisk er det bedst at det sker kontinuerligt. Hvis ikke du gider være syg før vaccinen kommer så hold dig hjemme. Men det bedste du kan gøre som ung er at blive smittet så hurtigt så muligt og hvis du er en af de meget få der får et kompliceret forløb så er du sikker på intensiv behandling da ikke ret mange er smittet endnu, men du skal skynde dig!
-
Genmab webcast præsentation på Deutsche Bank konference. 18. marts kl. 10 AM New York tid.
-
Finanznachrichten | Börsennews | finanzen.ch
Aktuelle Finanznachrichten rund um die Börse. Hier finden Sie ständig aktuelle Berichterstattung zu allen Anlagethemen.
finanzen.ch (www.finanzen.ch)
-
du kan registrere dig til konferencen på dette link https://www.adr.db.com/drwebrebrand/resources/dbvic
-
Du kunne også vælge at sidde yderst til forelæsningerne, det gjorde jeg altid, men det var for at komme først til kantinen og få noget kaffe. Jeg ville dog bare skippe de næste 2 uger hvis jeg var i dine sko, for sandsynligheden for at skolen lukker om 2 uger er nok 80%, men det vil nok kunne aflæses på tallene de næste dage hvorvidt vi ender der. -
** Gilead's GILD.O experimental coronavirus drug remdesivir could have a benefit, but mostly for patients in early stages of the disease and with lower viral load, says Jefferies
** Brokerage's view comes after discussion with an expert who held a conservative view on chances of hugely positive trial results from ongoing remdesivir trials
** Expert tells brokerage it may be unlikely that GILD's drug is doing extremely well in China as trials are still placebo controlled and the government has no -
not yet begun administering drug to all patients - Jefferies
** Late-stage study data for remdesivir might come early April or sooner and even marginal benefit of 10%-20% would be considered success given global unmet medical need - Jefferies
** GILD up 3% at $75.80 in premarket trading
** Expert also tells brokerage that, so far analysis shows that the genetic sequence of coronavirus is relatively stable, which may bode well for vaccine and antibody developers such as Regeneron REGN.O and Moder -
Moderna MRNA.O
** Up to Monday's close, Gilead had risen 13% YTD while REGN and MRNA are up between 24%-26% for the same period -
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab https://www.clinicaltrials.gov/ct2/show/NCT04302324?cond=Multiple+Myeloma&sfpd_s=02%2F25%2F2020&sfpd_d=14&sel_rss=new14
-
Stocks are rallying in the final hour of trading as Wall Street measures fiscal stimulus
-
Morgan Stanley raises EPS estimates for Genmab Morgan Stanley analyst Matthew Harrison maintained an Overweight rating and $31 price target on Genmab and raised his EPS estimates for FY20 and FY21.
The Fly | LANDINGPAGENEWS.PHP
Real-time market news, financial data, stock research, and portfolio tools from The Fly.
(thefly.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind